Morgan Stanley has released a report asserting that it believes the stock price of SINOPHARM (01099) is set to rise in the next 30 days, with a probability of 70% to 80%. The rating is “Overweight,” with a target price of HK$22.5. The report indicates that drug distributors have remained largely overlooked by the market in 2025 due to weak domestic demand and the impact of China’s technology licensing activities. Considering a 6.5 times price-to-earnings ratio for 2026, SINOPHARM is seen as having a favorable entry opportunity at this time.
Morgan Stanley explained that two subsidiaries of SINOPHARM have released their third-quarter performance, showing a positive turnaround quarter-on-quarter, which is expected to have a beneficial effect on the group. Notably, Sinopharm’s subsidiary, <600511.SH>, which acts as the distributor in Beijing and the main supplier of anesthetic drugs nationwide, reported a revenue and profit increase of 4% and 13%, respectively, year-on-year in the third quarter. Meanwhile, <000028.SZ>, the company responsible for SINOPHARM’s southern distribution network and Guoda Pharmacy chain, saw its revenue and net profit decline by 2% and 10% year-on-year in the third quarter, respectively. However, the company noted that its distribution business has now “stabilized and is recovering growth.”
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.